Emodin as a Covalent EGFR Inhibitor Inducing Ferroptotic Senolysis

Hypothesis

Emodin exerts senolytic activity by directly inhibiting EGFR autophosphorylation through covalent modification of a cysteine residue in its kinase domain, thereby suppressing EGFR‑STAT3 survival signaling in senescent cells and shifting the balance toward ferroptotic death.

Rationale

• Emodin’s anti‑inflammatory actions (TLR4/MyD88 blockade, NLRP3 suppression) are well documented [https://pmc.ncbi.nlm.nih.gov/articles/PMC8504117/].
• In cancer cells, emodin sensitizes to EGFR inhibitors by reducing STAT3 phosphorylation [https://pmc.ncbi.nlm.nih.gov/articles/PMC6756157/], yet direct EGFR binding is unconfirmed.
• The anthraquinone scaffold can act as a Michael acceptor, targeting nucleophilic cysteines in proteins (e.g., KEAP1, IKKβ). A similar mechanism could inhibit EGFR.
• Senescent cells often display heightened EGFR‑STAT3 activity that supports their survival SASP.
• Ferroptosis pathways are modulated by emodin [https://pmc.ncbi.nlm.nih.gov/articles/PMC12985997/]; loss of EGFR‑STAT3 signaling can sensitize to lipid peroxidation.

Predictions

1. In vitro, emodin will decrease phospho‑EGFR (Y1068) and phospho‑STAT3 (Y705) in p16^high^ senescent fibroblasts but not in proliferating counterparts.
2. This inhibition will be blocked by pre‑treatment with a thiol‑scavenger (N‑acetylcysteine), indicating covalent adduct formation.
3. Emodin‑treated senescent cells will show increased lipid ROS (C11‑BODIPY), reduced GPX4, and rescue by ferroptosis inhibitors (ferrostatin‑1) but not by caspase inhibitors.
4. Combining sub‑lethal emodin with a low dose of afatinib will produce synergistic senolysis, whereas the combination will be additive in proliferating cells.
5. In vivo, aged mice receiving emodin‑loaded nanoparticles will exhibit reduced p16^+^ cell burden in liver and kidney without affecting Ki‑67^+^ proliferating cells.

Experimental Design

• Cell models: IR‑induced senescent human fibroblasts (IMR‑90) and proliferating controls; validate senescence via SA‑β‑gal, p16/p21.
• Assays: Western blot for p‑EGFR, p‑STAT3; flow cytometry for Annexin V/PI; lipid ROS staining; viability (CellTiter‑Glo).
• Interventions: Emodin (5‑40 µM), NAC pretreatment, ferrostatin‑1, Z‑VAD‑FMK, afatinib (0.1‑1 µM).
• Readouts: Dose‑response curves, synergy (Bliss or Loewe).
• In vivo: 20‑month‑old mice, intravenous emodin‑lipid nanoparticles (10 mg/kg, twice weekly for 4 weeks); immunofluorescence for p16 and Ki‑67; serum SASP cytokines.

Potential Pitfalls & Alternatives

• If emodin does not affect p‑EGFR, the hypothesis is falsified; then we would test direct CDK4/6 inhibition as an alternative senolytic mechanism.
• Off‑target redox effects could confound ferroptosis readouts; using CRISPR‑KO of ACSL4 to confirm lipid‑dependency.